此外,太景於2013年4月也已經向中國大陸CFDA申請「太捷信」的上市許可,目前亦正在審查階段,若能通過審查且獲得上市許可,太捷信將成為台灣首例在ECFA兩岸衛生合作協議下,同時在兩岸上市的創新專利新藥。讓海峽兩岸的病患領先全球使用此一「Best in class」的創新藥物。
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
留言列表